Company intelligence / Profile preview

Immunovant, Inc.

New York City, New York, United Statesroivant.com ↗

Ownership: Public · IMVT
Employees: ~150
Development stage: Phase 3

Overview

Immunovant has reported positive results from its Phase 3 study of batoclimab in myasthenia gravis and initial results from a Phase 2b study in CIDP. High-dose batoclimab achieved significant response rates and IgG reduction in both MG and GD. The company will not seek approval for batoclimab but will use the data to advance its next-generation asset IMVT-1402 into registrational trials across up to ten indications by March 2026. Safety profiles have been consistent with prior studies.

Therapeutic areas: EndocrinologyNeurologyRheumatology
Modalities: monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

1 asset

IMVT-1402

Financials

Market cap: $7.9B
Total revenue: $7.1M
Enterprise value: $7.1B

Beyond the preview

Go deeper on Immunovant, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunovant, Inc..

Explore the full profile